YLYuqing Li

Yuqing Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuqing Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Bocun Li

    School of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, PR China

    2 shared publications
  • Hemei Li

    School of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, PR China

    2 shared publications
  • Jing Zhong

    School of Basic Medical Sciences, Guangxi University of Chinese Medicine, Nanning 530200, PR China

    2 shared publications
  • Lini Huo

    School of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, PR China

    2 shared publications
  • Panling Huang

    School of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, PR China

    2 shared publications
  • Shanliang Li

    School of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, PR China

    2 shared publications

Latest Publications

  • Panax notoginseng saponins protect PC12 cells against Aβ induced injury via promoting parkin-mediated mitophagy

    by Yixuan Jiang, Hemei Li, Panling Huang, Shanliang Li, Bocun Li, Lini Huo, Jing Zhong, Ziyu Pan, Yuqing Li, Xing Xia


  • Open Access

    Exploring the Mechanism of Panax notoginseng Saponins against Alzheimer’s Disease by Network Pharmacology and Experimental Validation

    by Yixuan Jiang, Shanliang Li, Xiaoqin Xie, Hemei Li, Panling Huang, Bocun Li, Lini Huo, Jing Zhong, Yuqing Li, Xing Xia

    Background. Panax notoginseng saponins (PNS) have been used for neurodegenerative disorders such as cerebral ischemia and Alzheimers disease (AD). Although increasing evidences show the neuron protective effects of PNS, the vital compounds and their functional targets remain elusive. To explore the potential functional ingredients of PNS for the AD treatment and their molecular mechanisms, an in vitro neuron injured model induced by Aβ was investigated, and the potential mechanism was predicted by network pharmacology approach and validated by molecular biology methods. Methods. Network pharmacology approach was used to reveal the relationship between ingredient-target disease and function-pathway of PNS on the treatment of AD. The active ingredients of PNS were collected from TCMSP, PubChem database, and literature mining in PubMed database. DrugBank and GeneCards database were used to predict potential targets for AD. The STRING database was performed to reveal enrichment of these target proteins, protein-protein interactions, and related pathways. Networks were visualized by utilizing Cytoscape software. The enrichment analysis was performed by the DAVID database. Finally, neuroprotective effect and predictive mechanism of PNS were investigated in an in vitro AD model established by Aβ25–35-treated PC12 cells. Results. An ingredient-target disease and function-pathway network demonstrated that 38 active ingredients were derived from PNS modulated 364 common targets shared by PNS and AD. GO and KEGG analysis, further clustering analysis, showed that mTOR signaling targets were associated with the neuroprotective effects of PNS. In Aβ-treated PC12 cells, PNS treatment improved neuroprotective effect, including mTOR inhibition and autophagy activation. Conclusions. Collectively, the protective effects of PNS on AD-neuron injury are related to the inhibition of mTOR and autophagy activation.